Business Context and Reporting Period
This Form 8-K was filed by Relmada Therapeutics, Inc. on April 27, 2017, reporting an event that occurred on April 21, 2017. The company is incorporated in Nevada and maintains its principal executive offices in New York, NY.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes.
Material Changes
On April 21, 2017, Dr. Richard Mangano resigned from his position as Chief Scientific Officer to return to academia. The company stated that his departure is not related to any issues regarding the Company's operations, policies, or practices. Dr. Mangano will continue to work with the Company as a consultant.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of material risks and contingencies beyond the personnel change. No unusual items were reported.
Key Facts for Investor Verification
- Dr. Richard Mangano resigned as Chief Scientific Officer on April 21, 2017.
- The resignation is attributed to a return to academia, not operational disputes.
- Dr. Mangano will remain engaged with the company in a consulting capacity.
- Sergio Traversa serves as both Chief Executive Officer and Interim Chief Financial Officer.